US/UK/Canada

Share

Contacts

  • Jonas Sohlman

    CEO


    Box 112, S-129 22 Hägersten Visiting address: Västertorpsvägen 135, S-129
    +46 (0) 70 576 30 73
    https://www.intervacc.se

    • Links

    Quotes

    The award of this significant grant from Eurostars, in partnership with Vinnova, is further endorsement of our vaccine technology, and it’s utility to improve the health of animals and profitability of farms
    CEO Jonas Sohlman
    This meeting, which is being supported jointly by Intervacc and Dechra Phamaceuticals, will bring together Europe’s leading experts on strangles to share experiences on strangles and the use of our vaccine in the field
    Jonas Sohlman, CEO
    The successful granting of this patent follows on from our earlier granted patent No. 11,155,585 and further strengthens Intervacc’s position in this important area of vaccine development
    Chief Scientific Officer Dr. Andrew Waller
    This new project represents another step on our path towards easing the burden caused by this important swine pathogen, in addition to minimising the requirement to treat this infection with antimicrobial agents
    Dr. Andrew Waller, CSO
    We are delighted to be working with Testa Center to develop the processes required to optimise the production of our prototype vaccine prior to scaling-up
    Dr. Andrew Waller, CSO of Intervacc
    2022 was a tough year for strangles cases and we’ve already seen several fatal cases of strangles in 2023. I’m really looking forward to working with vets throughout Europe to begin reversing this trend.
    Dr Andrew Waller, Chief Scientific Officer
    During 2022 Sport Horses were identified as the breed most at risk of being diagnosed with strangles, accounting for 37% of all strangles diagnoses in the UK. I’m incredibly excited about highlighting the new tools available to prevent this terrible disease and protect these amazing athletes as they participate in equestrian events throughout the world.
    Dr. Andrew Waller, Chief Scientific Officer
    I’m very pleased with the cooperation with Intervacc and we are excited to continue the work together with the development team. Together we are a leader in developing vaccines using recombinant fusion proteins, and we believe firmly that we are just at the beginning of this expanding field. This agreement confirms Intervacc and SLU’s long-term commitment to the project
    Bengt Guss, professor and project leader at SLU
    Streptococcus equi causes significant suffering in populations of horses in Italy. I have studied the strains recovered from Italian horses as they cause disease to better understand how this pathogen spreads. Therefore, I am delighted that we now have an additional tool with which to help keep our horses safe
    Dr. Silvia Preziuso, Università di Camerino
    I have investigated outbreaks of strangles in horses for many years, helping to track the causal agent, Streptococcus equi, as it spreads through horse populations around the world, including Poland. The launch of Strangvac in Poland provides us with a new tool to reduce the health and economic impact of this terrible disease, keeping our horses safe
    Dr Lucjan Witkowski from the Institute of Veterinary Medicine at University of Warsaw
    It’s a fantastic opportunity to speak about equine strangles directly to professionals at the London Vet Show. There are new and important tools in the preventative work against this terrible disease that causes much suffering among horses in the UK and throughout the world.
    Dr Andrew Waller, Chief Scientific Officer
    Strangvac is approved for sale and marketing in the EU as well as the UK, Norway, and Iceland. Strangvac has been launched in Sweden, Denmark, the UK, France, Germany, the Benelux region and now also in Ireland. Outbreaks of equine strangles occur regularly and the disease cause great suffering and economic cost in these regions and across Europe. Ireland is a very important equine market, and this is significant milestone for our continued launch around Europe.
    Andreas Andersson, CEO
    Strangvac is approved for sale and marketing in the EU as well as the UK, Norway and Iceland, and has been launched in Sweden, Denmark and in the UK. France, Germany, and the Benelux region are among the largest markets in Europe for equine vaccines. Outbreaks of equine strangles occur regularly and is the cause of great suffering and costs in these regions and across Europe. With the release, we have a finished product approved for launch in these countries. This is significant milestone for our continued launch around Europe.
    Andreas Andersson, CEO
    Strangles is highly contagious and is one of the most common equine infectious diseases with an estimated 600 outbreaks each year in the UK alone. Feared by many horse owners due to the potential severity of the clinical signs and the speed at which it can spread through an affected farm, we are sure the new strangles vaccine will be a vital tool and a huge benefit to the equestrian industry as a whole
    Sara Barker, equine field support manager at Dechra Pharmaceuticals PLC
    With our technology platform and vaccines, we have an opportunity to improve animal health and at the same time contribute to reducing the use of antibiotics. We are building an animal vaccine company with a global reach.
    Andreas Andersson, CEO
    This order from our distribution partner Dechra, will facilitate the launch of Strangvac in the first European countries outside Scandinavia.
    Andreas Andersson, CEO of Intervacc
    Strangvac is approved for sale and marketing in the EU as well as the UK, Norway and Iceland, and has been launched in Sweden and Denmark. The UK is expected to be one of the largest markets in Europe for vaccines against the highly contagious infectious disease equine strangles. With the release, we have a finished product approved for launch in the UK. This is significant milestone for our launch in Europe.
    Anderas Andersson, CEO of Intervacc
    We have passed another milestone in the fight against equine strangles when Denmark now becomes the first country outside Sweden where Strangvac is available for sale. We look forward to continuing the launch of Strangvac in Europe
    Andreas Andersson, CEO
    Our prototype vaccine uses fusions of several important proteins of Staphylococcus aureus and was safe when administered to pregnant heifers by intramuscular injection on three successive occasions. Vaccinated animals generated antibody responses to the vaccine components that were boosted after the second and third doses.
    Dr. Andrew Waller, Chief Scientific Officer
    Intervacc’s vaccine technology platform induces broad immune responses against complex bacterial pathogens and we are delighted that our prototype vaccine against Staphylococcus aureus is entering this proof-of-concept phase.
    Andreas Andersson, CEO
    Strangvac, Intervacc's vaccine against equine strangles, was approved in the autumn of 2021 for sale in Norway based on the European Medicines Agency's, EMA’s, recommendation. The change that the Norwegian Food Safety Authority has now implemented makes it possible for horses to be vaccinated against equine strangles in Norway. Our interpretation is that the change was implemented in response to Strangvac being approved and that the Norwegian Food Safety Authority made the assessment that vaccination with Strangvac is a new and welcome tool in the fight against equine strangles.
    Andreas Andersson, Chief Executive Officer
    It is really positive that the Norwegian authority has implemented this rule change and the timing is perfect as we have started to sell Strangvac in Sweden. Strangles outbreaks are common in Norway and we have begun the process of making the vaccine available to Norwegian veterinarians as soon as possible. However, with the change in the rules, Norwegian veterinarians can now bring in Strangvac from Sweden via license.
    Hege Drangsholt, country manager and product specialist
    This proof-of-concept study provides a solid foundation upon which to develop a new vaccine against this devastating disease
    Dr. Andrew Waller, Chief Scientific Officer
    An effective vaccine would improve the health of piglets and decrease the need to use antibiotics. Our aim is to significantly reduce the mortality rate among piglets during a time period where they are extremely vulnerable to infections
    Andreas Andersson, Chief Executive Officer
    We have passed many milestones along the way in the development of a vaccine against equine Strangles, going through the approval and manufacturing process, and we are now at the marketing launch. When Strangvac is now released for sale, we take the step into a new phase. It feels fantastic!
    CEO, Andreas Andersson
    The number of horses in the United States is estimated to be around 10 million representing the largest market for equine vaccines in the world. The filing represents a significant milestone for Intervacc and is a major step towards preventing outbreaks and suffering in horses. Strangles is the most frequently diagnosed contagious equine disease in the world and in the case of an outbreak, stables must be quarantined and owners often face great difficulties and costs.
    CEO Andreas Andersson
    It is good that we have this possibility to extend the market exclusivity in Europe. There is a similar system in place in the US that will allow us to extend the protection also there, after regulatory approval of Strangvac. We do however not expect any one to get approval for a biosimilar vaccine even after the patent and the SPC expires. In the chemical pharmaceutical industry generics are common, but it is much more rare for biological pharmaceuticals (so called biosimilars) and we do not know of any examples of approved vaccine-biosimilars. Our assessment is that Strangvac will become the leading vaccine against equine strangles globally and will continue to be so long after patents and supplementary protection have expired
    CEO Andreas Andersson
    The granted patent is a very important step in developing a vaccine against Streptococcus suis infections which is a serious problem in the pig industry. S. suis infections are treated with antibiotics and a vaccine is also important in the fight against the development of antibiotic-resistant bacteria. Intervacc's technology platform provides vaccines with DIVA capacity, i.e. the ability to distinguish a vaccinated animal from an infected animal. This is especially important when dealing with an endemic zoonotic bacteria that can also affect humans and where the vaccine is used to protect food-producing animals. We use the same technology with recombinant fusion proteins that we used in our vaccine against the horse disease strangles that was recently approved by EMA and we see great opportunities to develop more vaccines based on the same technology.
    Andreas Andersson, CEO
    The technology behind this patent has been developed in collaboration with world-leading researchers at the Karolinska Institutet and the Swedish University of Agricultural Sciences, SLU over a period of many years. We are very pleased to, with the help of this ground-breaking research, obtain a patent that could lead to a vaccine for pigs against this widespread and often deadly infectious disease.
    Dr. Andrew Waller, Chief Scientific Officer
    We are delighted that Strangvac has been granted a market authorisation in the UK. Up to 600 outbreaks of strangles occur in the UK each year, impacting thousands of horses and we feel a great responsibility to apply this new vaccine to improve the health of horses
    Andreas Andersson, CEO of Intervacc
    We are very pleased that NoMA has granted a marketing authorization for Strangvac in Norway. The approval follows the positive opinion given by the European Medicines Agency, EMA, in June this year. This is an important step since we now can market the vaccine throughout the Nordic region as equine strangles does not respect borders and affects horses and the horse industry in our neighbouring countries and we feel great responsibility to spread the use of the vaccine to improve the health of horses.
    Andreas Andersson, CEO
    We are happy that Strangvac has received the European Commission’s approval. Strangvac is the first Swedish Animal Health vaccine to be approved through the centralised procedure and we feel great responsibility to spread the use the vaccine to improve the health of horses across the European Union.
    Andreas Andersson, CEO
    Strangles is endemic in horse populations throughout the world and causes incalculable suffering, stress and economic cost to the equine industry within Europe. The development of Strangvac has been achieved in partnership with world-leading scientists at the Karolinska Institute and the Swedish University of Agricultural Sciences. We are excited about applying this ground-breaking science to prevent such an important disease of horses.
    Dr Andrew Waller, Chief Scientific Officer
    We are delighted to receive this positive outcome from the VMD in the UK. Our application now enters a 30-day sign-off phase followed by a 10-day issue phase, leading up to an approval for the UK market in approximately 40 days time. Up to 600 outbreaks of strangles outbreaks occur in the UK each year, impacting thousands of horses and this is an important milestone for our company as we move towards launching Strangvac
    Andreas Andersson, CEO
    We are very excited to receive a positive opinion from the CVMP. It is a long-awaited vaccine and an important step for the company as we move on to launch in the European market after approval.
    Andreas Andersson, CEO
    This vaccine is a game-changer in our work to combat equine strangles by providing veterinarians with a valuable tool that can be used alongside current strategies to prevent outbreaks of this devastating disease. I am really delighted to continue the work on the launch of our vaccine.
    Emma Hartman, DVM and global product manager
    Our vaccine is the first Swedish Animal Health vaccine to receive a positive opinion through the centralised procedure at the European Medicines Agency and it represents a milestone for a new generation of recombinant protein vaccines. We continue to work with the same technology to develop more vaccines to improve animal health, most notably against Staphylococcus aureus in cows and Streptococcus suis in pigs.
    Dr. Andrew Waller, Chief Scientific Officer
    It is really fantastic that we can continue the collaboration with the research team at KI, a great team with many years of experience in bacteriological research and vaccine development. Their contribution will be of great importance for our ongoing vaccine development projects.
    Dr. Andrew Waller Chief Scientific Officer, Intervacc
    I’m very pleased with the cooperation with Intervacc and we are excited to continue our work together with the development team. Together we are a leader in developing vaccines using fusions of recombinant proteins and recombinant vaccine technologies. This agreement confirms Intervacc and KI’s long-term commitment to the project.
    Professor Birgitta Henriques Normark, Karolinska Institutet
    We are excited to be entering into this partnership with Dechra to expand Strangvac’s market reach in Europe, where there is a significant medical need to prevent this highly contagious, debilitating disease. We selected Dechra as our exclusive partner as they are a high growth, global specialist veterinary business with a particular strength in the equine market. We look forward to working in close collaboration with Dechra to bring the innovative approach of Strangvac, which has shown great promise in clinical trials, to the European equine community as rapidly as possible.
    Andreas Andersson, CEO Intervacc
    We are delighted to enter this collaboration with Intervacc. The addition of Strangvac will further strengthen our established European equine range by providing veterinarians with a novel product helping to prevent strangles in horses.
    Ian Page, CEO Dechra
    Upon approval, Strangvac will be the first Swedish Animal Health Vaccine to receive marketing authorization by the centralised EMA procedure covering all 27 member states of the European Union (E.U.), as well as Iceland, Liechtenstein and Norway. The UK has also decided to follow the EMA approval up until at least first of January 2023
    Dr Andrew Waller, Chief Scientific Officer
    I am really delighted to be joining Intervacc to work on the global launch of Strangvac. The recombinant fusion protein technology that is used within Strangvac can finally break the cycle of S. equi infection and I am thrilled by this opportunity to provide a vaccine that will be of enormous benefit to horse owners and their horses throughout the world.
    Emma Hartman, Global Product Manager Strangvac
    Emma brings extensive knowledge of vaccines and animal health products to Intervacc and will play a vital role in the success of Strangvac. In recent years, she has worked with education, sales, and marketing of veterinary pharmaceuticals at one of the world-leading, global animal health companies. In particular, she has worked with one of the leading vaccines against equine influenza. She has a passionate interest in horse welfare, and it will be fantastic to work with Emma on the launch of Strangvac
    Andreas Andersson, CEO
    I’m very pleased with the cooperation with Intervacc and we are excited to continue the work together with the development team. Together we are a leader in developing vaccines using fusions of recombinant proteins, and we believe firmly that we are only in the beginning of this expanding field. This agreement confirms Intervacc and KI’s long-term commitment to the project.
    Professor Birgitta Henriques Normark, Karolinska Institutet
    We are really pleased to be able to continue to collaborate with a recognized research team led by Professor Birgitta Henriques Normark. Intervacc is very pleased with the results that our research teams at KI and SLU have achieved together. We are at the forefront of some very innovative animal health vaccine technologies and we are excited about the ability to utilize this knowledge within vaccinology to bring new animal health vaccines to the market
    Andreas Andersson, CEO Intervacc AB
    I am excited that we have been able to recruit yet another strong and leading researcher to Intervacc. Andrew adds a fantastic energy and competence in the very important launch of our strangles vaccine, as well as in the further development of our promising pipeline projects
    Andreas Andersson, CEO
    The technology at the heart of Strangvac directs an immune response to simultaneously target an array of proteins used by invading bacteria and has enormous potential for the development of new vaccines with which to improve animal health
    Dr. Andrew Waller
    The study illustrates how Strangvac can be used to prevent horses from developing strangles if they should be exposed to Streptococcus equi. Our results also suggest that Strangvac will play an important role in improving health and welfare of the horses and minimizing economic impact of outbreaks
    CSO prof. Jan-Ingmar Flock
    This is a very good validation of our operations and our vaccine technology, as well as of our vaccine candidates against mastitis in dairy cows. Vinnova has selected our innovation project in the face of strong competition from other Swedish development projects, all with the potential to achieve international success. We can now strengthen our activities in this vaccine development in our exciting project portfolio of modern vaccines
    Jan-Ingmar Flock, chief scientific officer
    Pick a time period -
    Tags ( Active)
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media